Table 3.
Treatment patterns in patients with SCD with recurrent VOCsa
| Patients with SCD with recurrent VOCs (N = 3420) | |
|---|---|
| Treatment claims, n (%)b | |
| Pain medications | 3366 (98.4) |
| Opioidsc | 3200 (93.6) |
| NSAIDs | 3049 (89.2) |
| Gabapentin | 622 (18.2) |
| Folic acid | 2432 (71.1) |
| Hydroxyurea | 2325 (68.0) |
| Penicillin | 924 (27.0) |
| Iron chelation therapy | 468 (13.7) |
| Treatment claims PPPY, mean (SD)b | |
| Pain medications | 13.1 (14.6) |
| Opioidsc | 9.7 (12.9) |
| NSAIDs | 3.0 (3.5) |
| Gabapentin | 0.3 (1.3) |
| Folic acid | 2.6 (3.1) |
| Hydroxyurea | 2.6 (3.2) |
| Penicillin | 1.1 (3.7) |
| Iron chelation therapy | 0.6 (3.1) |
NSAID non-steroidal anti-inflammatory drug; PPPY per patient per year; SCD sickle cell disease; SD standard deviation; VOC vaso-occlusive crisis
aData were assessed during the variable-length follow-up, beginning on the index date and ending on the earliest date of either inpatient death, end of continuous enrollment, or end of the study period (March 1, 2020)
bData are presented for all patients with SCD with recurrent VOCs
cOpioids included buprenorphine, dihydrocodeine, fentanyl, hydromorphone, morphine, oxycodone, tramadol, and Tylenol with codeine